• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Gliflozins in Cardiac and Renal Disease Gliflozins—sodium–glucose cotransporter 2
inhibitors—lower blood glucose and glycated hemoglobin in patients with type 2 diabetes …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Despite major advancements in cardiovascular medicine, sudden cardiac death (SCD)
continues to be an enormous medical and societal challenge, claiming millions of lives …

Importance In 2 trials enrolling patients with heart failure (HF) across the spectrum of
ejection fraction (EF), dapagliflozin has been shown to reduce the rate of the composite of …

Background Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant
cardiovascular benefits in patients with and without type 2 diabetes mellitus (T2DM). They …

Polycystic ovary syndrome (PCOS) is a complex endocrinopathy affecting many women of
reproductive age. Although its physiology is poorly understood, hyperandrogenemia and …

ABSTRACT Introduction Sodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known
as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent …

The prevention of cardiac life-threatening ventricular fibrillation and stroke-provoking atrial
fibrillation remains a serious global clinical issue, with ongoing need for novel approaches …

Background Malignant ventricular arrhythmia (VA) is a major contributor to sudden cardiac
death (SCD) in patients with pulmonary arterial hypertension (PAH)-induced right heart …